Dermatophytic Onychomycosis Treatment Market Study by New Business Strategies by Top Key Players Operating Globally Johnson & Johnson, Novartis AG, Pfizer Inc, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc.

Nail onychomycosis or fungus infection is caused by a fungus called Trichophyton rubrum and Trichophyton mentagrophytes. However, few cases may also be caused by yeasts and molds. Fungi grow and spread due to conditions of warmth and moisture. The infection begins as a white or yellow spot under the tip of the nail and as it spreads deeper into the nail, it causes potentially painful nail discoloration, thickening, and development of crumbling edges. Onychomycosis commonly affects toenails than in fingernails, as toenails are often confined in a dark, warm, moist environment inside shoes where fungi can thrive. Old age people are more likely to be affected by the disease due to suppressed nail growth and immunity, and other complications.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2053

The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).

Market Dynamics

Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.

Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.

Dermatophytic Onychomycosis Treatment Market - Top Key Vendors Operating Globally

Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma.

Request for Customizarion of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2053

Dermatophytic Onychomycosis Treatment Market - Market Taxonomy:

Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:
Systemic Therapy
Topical Therapy
Device-based Therapy

Global Dermatophytic Onychomycosis Treatment Market, By End User:
Hospitals
Dermatology Clinics
Retail Pharmacies
Others

Key features of the study:

This report provides in-depth analysis of dermatophytic onychomycosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2018 – 2026), considering 2017, as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc, GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the dermatophytic onychomycosis treatment market.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.